Telehealth-Based Chronic Disease Management for Type 2 Diabetes
T2DMTH
Application and Evaluation of Telehealth-Based Chronic Disease Management for Type 2 Diabetes
1 other identifier
observational
1,636
0 countries
N/A
Brief Summary
This study will be conducted from enrollment until the end of the six-month follow-up period. This study aims to assess the impact of the Internet hospital online + offline integrated chronic disease management model on patients with type 2 diabetes mellitus. It will also evaluate the economic impact of the model and identify the characteristics of the appropriate population for the model. Finally, it will develop a toolkit to help manage chronic diseases. The study will include 1,636 patients with type 2 diabetes who did not reach the standard of control target of glucose, blood pressure or LDL at the endocrine outpatient clinic and inpatient wards of the Third Hospital of Peking University. We will collect information from participants before the study starts. And the patients will be followed up for 6 months from enrollment. The study management mode included online and offline integrated management in the Internet hospital, and routine offline management mode. After completing the enrollment and assessment, we will arrange outpatient follow-up and management according to the current status, doctor's requirements, and study subjects' needs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2024
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 28, 2024
CompletedFirst Posted
Study publicly available on registry
December 5, 2024
CompletedStudy Start
First participant enrolled
December 18, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
December 5, 2024
December 1, 2024
2 years
November 28, 2024
December 2, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
the proportion of patients achieved all three targets (HbA1c < 7.0%, blood pressure < 130/80 mmHg and LDL-cholesterol < 2.6 mmol/L)
at 6±1 month from the enrollment
Secondary Outcomes (22)
patient adherence using 8-item Morisky Medication Adherence Scale (MMAS-8)
at 3±1 month from the enrollment
patient satisfaction using Visual Analogue Scale (VAS)
at 3±1 month from the enrollment
Hypoglycemic events
at 3±1 month from the enrollment
Acute complications
at 3±1 month from the enrollment
Hospitalization for any reason
at 3±1 month from the enrollment
- +17 more secondary outcomes
Study Arms (2)
online + offline integrated management in the Internet hospital
Routine offline management mode
Eligibility Criteria
The study will include patients with type 2 diabetes who did not meet the control target of glucose, blood presure or LDL at the endocrine outpatient clinic and inpatient wards of the Third Hospital of Peking University.
You may qualify if:
- years old;
- Confirmed diagnosis of type 2 diabetes mellitus;
- Ability to use smartphones to participate in online diagnosis and treatment;
- Ability of the patient or relatives to assist the patient in self-monitoring of blood glucose;
- Failure to meet control targets: glycated hemoglobin ≥7. 0%, or LDL-C ≥ 2.6 mmol/L (and ASCVD or definite atherosclerosis with stenosis ≥ 1.8 mmol/L), or blood pressure \> 130% and ≥ 1.8 mmol/kg. L), or blood pressure over 130/80 mmHg.
You may not qualify if:
- Mental illness, cognitive dysfunction;
- Other diseases and complex conditions (untreated tumors, heart disease within 3 months);
- Acute complications of diabetes, severe hyperglycemia, fasting glucose greater than 16.9 mmol / L, random glucose greater than 20 mmol / L. Diabetic ketoacidosis and hypoglycemic coma that are not suitable for online management of diabetes emergencies;
- Patients with severe chronic complications of diabetes in critical condition (blindness, vision deterioration, new onset of ASCVD symptoms);
- Those who are unsuitable for the study: infection, fracture, trauma, foot ulceration, edema, blindness, cardiovascular emergencies, coma, etc;
- Those who have not signed the informed consent form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zeng Lin, Ph. D.lead
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Deputy Director of Peking University Third Hospital Research Center of Clinical Epidemiology
Study Record Dates
First Submitted
November 28, 2024
First Posted
December 5, 2024
Study Start
December 18, 2024
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2027
Last Updated
December 5, 2024
Record last verified: 2024-12